ProbodyTM therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the tumor microenvironment. Their target-binding regions are masked to limit activity —and toxicity— in healthy tissue. When Probody therapeutics encounter active proteases near tumor tissue, their substrates are designed to be cleaved, removing their masks and activating them to bind to their tumor targets, potentially turning the disease against itself.
With Probody therapeutics, we have the potential to:
- Create or widen the therapeutic window—the range of a drug’s dosage that is effective without causing unacceptable toxicity
- Enable new combinations previously not possible due to toxicities
- Expand the universe of drug targets previously considered “undruggable” due to the target’s presence on health tissues
- Make new treatment options possible, so that more patients can benefit
More information about protease biology can be found in our fact sheet.